Kearns, Jeffrey D.
2Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
3 papers on CoChatORCID 0000-0001-7261-5096
Most cited papers
- Verified
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C
Weiss, A., Lorthiois, E., Barys, L., Beyer, K. S., Bomio-Confaglia, C., Burks, H., Chen, X., Cui, X., de Kanter, R., Dharmarajan, L., et al. (2022) · Cancer Discovery
Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways
Cited by 150
- Verified
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
Arena, S., Siravegna, G., Mussolin, B., Kearns, J. D., Wolf, B. B., Misale, S., Lazzari, L., Bertotti, A., Trusolino, L., Adjei, A. A., et al. (2016) · Science Translational Medicine
Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations
Cited by 93
- Verified
Safety, pharmacology, and preliminary clinical activity of MM-151: An oligocolnal anti-EGFR theraputic in patients with cetuximab-resistant CRC and other refractory solid tumors.
Lieu, C. H., Beeram, M., Harb, W. A., Kearns, J. D., Sloss, C. M., Nering, R., Adjei, A. A., & Wolf, B. B. (2015) · Journal of Clinical Oncology
Colorectal Cancer Treatments and StudiesMonoclonal and Polyclonal Antibodies Research
Cited by 7
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free